All In Biotech

Drug Trial Radar · NCT07566195

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

A Phase III, Multicentre, Open-Label, Chronic Dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

59

Planned (sponsor's estimate)

Start

May 5, 2026

Primary completion

Dec 29, 2028

Study completion Dec 29, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Clinact, Multihealth Group; Contract Research Organization
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations. Eligible participants must have completed one of the predecessor studies.

Conditions

  • Chronic Obstructive Pulmonary Disease
  • COPD

Interventions

  • Tozorakimab Dose Regimen 1Drug

    Participants previously randomised in the MIRANDA predecessor study will receive Tozorakimab in ROMEO according to this dose regimen

  • Tozorakimab Dose Regimen 2Drug

    Participants previously randomised in the TITANIA or PROSPERO predecessor studies will receive Tozorakimab in ROMEO according to this dose regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: 2-3 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Aix-en-Provence, France · Active not recruiting

  • Research Site

    Brest, France · Active not recruiting

  • Research Site

    Colmar, France · Withdrawn

  • Research Site

    Gleizé, France · Active not recruiting

  • Research Site

    Grenoble, France · Recruiting

  • Research Site

    Lyon, France · Recruiting

  • Research Site

    Marseille, France · Recruiting

  • Research Site

    Montpellier, France · Recruiting

  • Research Site

    Pessac, France · Recruiting

  • Research Site

    Pringy, France · Active not recruiting

  • Research Site

    Quimper, France · Active not recruiting

  • Research Site

    Saint-Herblain, France · Active not recruiting

  • Research Site

    Toulouse, France · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.